On Aug. 4, 2022, Novavax announced the initiation of its Phase 2b/3 Hummingbird global clinical trial. The trial evaluates the safety, effectiveness (immunogenicity), and efficacy of two doses of the Novavax COVID-19 vaccine (NVX-CoV2373) in younger children aged six months through 11 years, followed by a booster at six months after the primary vaccination series.

The trial assessed the Novavax COVID-19 vaccine in infants (six through 23 months of age), toddlers (two through five years) and children (six through 11 years). The trial was an age de-escalation trial and age groups was tested sequentially. Participants had begun dosing in the six to 11-year-old age group. The trial also had sentinel cohorts in each age group and cohort progression and age-de-escalation will occur after safety review.